EHA 2019 | AML & Myelodysplasia breakthrough
Paresh Vyas
• 15 Jun 2019
For a time there had been very few new treatments for acute myeloid leukemia (AML) and Myelodysplasia, and recently there has been an ‘avalanche’ of new treatments for these diseases. Paresh Vyas, MRCP, FRCP, FRCPath, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, tells us about the extremely positive responses seen in the use of a new monoclonal antibody in combination with azacitidine. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
